At least six companies have emerged to help unstick what developers say is a “bottleneck” in advancing complex genetic treatments. Editor’s note: BioPharma Dive, as part of Emerging Biotech Weekly, is taking a closer look at competitive areas of startup activity. We aim
The Science Behind NMN–A Stable, Reliable NAD+Activator and Anti-Aging Molecule
In June 2018, the World Health Organization (WHO) released the 11th edition of its International Classification of Diseases and added aging for the first time. The classification of aging as a disease paves the way for new research into novel therapeutics to
Targeting NAD+ Metabolism as Interventions for Mitochondrial Disease
Abstract Leigh syndrome is a mitochondrial disease characterized by neurological disorders, metabolic abnormalities, and premature death. There is no cure for Leigh syndrome; therefore, new therapeutic targets are urgently needed. In Ndufs4-KO mice, a mouse model of Leigh syndrome, we